Pharma Focus Asia

CARsgen Therapeutics Opens New U.S. cGMP Facility for CAR T Production

Tuesday, February 22, 2022

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies announced that its current Good Manufacturing Practices (cGMP) manufacturing facility located at the Research Triangle Park (RTP) in North Carolina, the United States of America ("The RTP Manufacturing Facility") has successfully passed the official inspections by local government. CARsgen has received the Certificate of Compliance from the City-County Inspections Department of Durham, enabling CARsgen to advance to clinical manufacturing.

The commencement of operations at the state-of-the-art RTP Manufacturing Facility, with a total gross floor area of approximately 3,300 sq.m, will provide CARsgen additional manufacturing capacity of autologous CAR T-cell products for 700 patients annually. The RTP Manufacturing Facility will support the company's clinical studies and early commercial launch in North America and Europe. CARsgen is building a world-class CMC team for the RTP manufacturing facility operations. The RTP Manufacturing Facility project adopted an integrated project delivery approach that greatly shortens construction turnaround time and improves cost effectiveness. This project received the Job Development Investment Grant (JDIG) award and other investment incentives from North Carolina state, Durham County and Durham City.

"We're all pleased to celebrate grand opening of CARsgen's first U.S. cGMP manufacturing facility, which is an instrumental step in our global strategy. RTP manufacturing facility plus two CARsgen existing GMP facilities in Shanghai, China will enhance our global manufacturing capacity, strengthen supply chain sustainability, advance our clinical studies, and position CARsgen for early commercial launch. Most of all, it will help CARsgen deliver an effective treatment with substantial survival benefit to the patients around the world," said Mr. Richard John Daly, President of CARsgen Therapeutics Corporation (a subsidiary of CARsgen Therapeutics Holdings Limited in the United States).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Adopting the Power of AI to Drug Development ProjectsROUQETTE - Pharma Virtual LabDUPHAT 2024Thermo Fisher Scientific - Rapid Mycoplasma TestingAsia Healthcare Week 20247th Annual Pharma Project & Portfolio Management 2024CHEMICAL INDONESIA 2024INALAB 2024The Drug Safety Symposium 2024Medlab Middle East 2024ISPE Singapore Affiliate Conference & Exhibition 2024